MedTrace Logo

Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones

NCT05778695 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-02-12

Study results available
· View outcomes & findings →

Summary

Small exploratory open-label pilot study to assess supplementation of a ketone ester (KetoneAid) as a potential therapy for persons with Parkinson disease (PD), Parkinson Disease Dementia/Lewy Body Dementia (PDD/LBD), and healthy controls.

Conditions

  • Parkinson Disease
  • Lewy Body Dementia
  • Parkinson Disease Dementia

Interventions

DIETARY_SUPPLEMENT

Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate

Ketone ester (KE) dietary supplement (KetoneAid)

Sponsors & Collaborators

Principal Investigators

  • Nicolaas Bohnen, MD · University of Michigan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-09
Primary Completion
2023-10-04
Completion
2023-10-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05778695 on ClinicalTrials.gov